News headlines about Sarepta Therapeutics (NASDAQ:SRPT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.2232532012363 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media headlines that may have effected Accern’s rankings:

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded down $0.21 during mid-day trading on Thursday, hitting $63.01. 1,366,630 shares of the stock traded hands, compared to its average volume of 1,753,900. Sarepta Therapeutics has a one year low of $28.14 and a one year high of $68.90. The firm has a market cap of $4,070.00, a price-to-earnings ratio of -30.89 and a beta of 1.49. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.

A number of research firms have commented on SRPT. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Monday, February 12th. Oppenheimer reaffirmed a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 10th. Royal Bank of Canada began coverage on shares of Sarepta Therapeutics in a report on Monday, January 22nd. They set an “outperform” rating for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $77.00 target price on shares of Sarepta Therapeutics in a report on Friday, January 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have given a buy rating to the company. Sarepta Therapeutics presently has an average rating of “Buy” and an average price target of $66.15.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.60% of the stock is owned by insiders.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with's FREE daily email newsletter.